Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: HSBC
Deal Size: $11.1 million Upfront Cash: Undisclosed
Deal Type: Financing June 08, 2020
Details:
The financing will help ensure the company have the necessary resources to continue achieving its goals to advance the development of NBTXR3.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
